These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

982 related articles for article (PubMed ID: 28257752)

  • 1. Efficacy and safety of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukaemia: an open-label, randomised phase 3 trial.
    Jones JA; Robak T; Brown JR; Awan FT; Badoux X; Coutre S; Loscertales J; Taylor K; Vandenberghe E; Wach M; Wagner-Johnston N; Ysebaert L; Dreiling L; Dubowy R; Xing G; Flinn IW; Owen C
    Lancet Haematol; 2017 Mar; 4(3):e114-e126. PubMed ID: 28257752
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial.
    Zelenetz AD; Barrientos JC; Brown JR; Coiffier B; Delgado J; Egyed M; Ghia P; Illés Á; Jurczak W; Marlton P; Montillo M; Morschhauser F; Pristupa AS; Robak T; Sharman JP; Simpson D; Smolej L; Tausch E; Adewoye AH; Dreiling LK; Kim Y; Stilgenbauer S; Hillmen P
    Lancet Oncol; 2017 Mar; 18(3):297-311. PubMed ID: 28139405
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ublituximab plus ibrutinib versus ibrutinib alone for patients with relapsed or refractory high-risk chronic lymphocytic leukaemia (GENUINE): a phase 3, multicentre, open-label, randomised trial.
    Sharman JP; Brander DM; Mato AR; Ghosh N; Schuster SJ; Kambhampati S; Burke JM; Lansigan F; Schreeder MT; Lunin SD; Zweibach A; Shtivelband M; Travis PM; Chandler JC; Kolibaba KS; Sportelli P; Miskin HP; Weiss MS; Flinn IW
    Lancet Haematol; 2021 Apr; 8(4):e254-e266. PubMed ID: 33631112
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ofatumumab maintenance versus observation in relapsed chronic lymphocytic leukaemia (PROLONG): an open-label, multicentre, randomised phase 3 study.
    van Oers MH; Kuliczkowski K; Smolej L; Petrini M; Offner F; Grosicki S; Levin MD; Gupta I; Phillips J; Williams V; Manson S; Lisby S; Geisler C;
    Lancet Oncol; 2015 Oct; 16(13):1370-9. PubMed ID: 26377300
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study.
    Chanan-Khan A; Cramer P; Demirkan F; Fraser G; Silva RS; Grosicki S; Pristupa A; Janssens A; Mayer J; Bartlett NL; Dilhuydy MS; Pylypenko H; Loscertales J; Avigdor A; Rule S; Villa D; Samoilova O; Panagiotidis P; Goy A; Mato A; Pavlovsky MA; Karlsson C; Mahler M; Salman M; Sun S; Phelps C; Balasubramanian S; Howes A; Hallek M;
    Lancet Oncol; 2016 Feb; 17(2):200-211. PubMed ID: 26655421
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trial.
    Hillmen P; Robak T; Janssens A; Babu KG; Kloczko J; Grosicki S; Doubek M; Panagiotidis P; Kimby E; Schuh A; Pettitt AR; Boyd T; Montillo M; Gupta IV; Wright O; Dixon I; Carey JL; Chang CN; Lisby S; McKeown A; Offner F;
    Lancet; 2015 May; 385(9980):1873-83. PubMed ID: 25882396
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and tolerability of idelalisib, lenalidomide, and rituximab in relapsed and refractory lymphoma: the Alliance for Clinical Trials in Oncology A051201 and A051202 phase 1 trials.
    Smith SM; Pitcher BN; Jung SH; Bartlett NL; Wagner-Johnston N; Park SI; Richards KL; Cashen AF; Jaslowski A; Smith SE; Cheson BD; Hsi E; Leonard JP
    Lancet Haematol; 2017 Apr; 4(4):e176-e182. PubMed ID: 28314699
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia.
    Furman RR; Sharman JP; Coutre SE; Cheson BD; Pagel JM; Hillmen P; Barrientos JC; Zelenetz AD; Kipps TJ; Flinn I; Ghia P; Eradat H; Ervin T; Lamanna N; Coiffier B; Pettitt AR; Ma S; Stilgenbauer S; Cramer P; Aiello M; Johnson DM; Miller LL; Li D; Jahn TM; Dansey RD; Hallek M; O'Brien SM
    N Engl J Med; 2014 Mar; 370(11):997-1007. PubMed ID: 24450857
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy results of a phase 2 trial of first-line idelalisib plus ofatumumab in chronic lymphocytic leukemia.
    Lampson BL; Kim HT; Davids MS; Abramson JS; Freedman AS; Jacobson CA; Armand PA; Joyce RM; Arnason JE; Rassenti LZ; Kipps TJ; Fein J; Fernandes SM; Hanna JR; Fisher DC; Brown JR
    Blood Adv; 2019 Apr; 3(7):1167-1174. PubMed ID: 30967392
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial treatment for younger patients with chronic lymphocytic leukaemia: a single-arm, multicentre, phase 2 trial.
    Davids MS; Brander DM; Kim HT; Tyekucheva S; Bsat J; Savell A; Hellman JM; Bazemore J; Francoeur K; Alencar A; Shune L; Omaira M; Jacobson CA; Armand P; Ng S; Crombie J; LaCasce AS; Arnason J; Hochberg EP; Takvorian RW; Abramson JS; Fisher DC; Brown JR;
    Lancet Haematol; 2019 Aug; 6(8):e419-e428. PubMed ID: 31208944
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Indirect Treatment Comparisons of Ibrutinib Versus Physician's Choice and Idelalisib Plus Ofatumumab in Patients With Previously Treated Chronic Lymphocytic Leukemia.
    Sorensen S; Wildgust M; Sengupta N; Trambitas C; Diels J; van Sanden S; Xu Y; Dorman E
    Clin Ther; 2017 Jan; 39(1):178-189.e5. PubMed ID: 28062113
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lenalidomide maintenance therapy in previously treated chronic lymphocytic leukaemia (CONTINUUM): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Chanan-Khan AA; Zaritskey A; Egyed M; Vokurka S; Semochkin S; Schuh A; Kassis J; Simpson D; Zhang J; Purse B; Foà R
    Lancet Haematol; 2017 Nov; 4(11):e534-e543. PubMed ID: 28958469
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rituximab, ofatumumab and other monoclonal anti-CD20 antibodies for chronic lymphocytic leukaemia.
    Bauer K; Rancea M; Roloff V; Elter T; Hallek M; Engert A; Skoetz N
    Cochrane Database Syst Rev; 2012 Nov; 11(11):CD008079. PubMed ID: 23152253
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fludarabine plus alemtuzumab versus fludarabine alone in patients with previously treated chronic lymphocytic leukaemia: a randomised phase 3 trial.
    Elter T; Gercheva-Kyuchukova L; Pylylpenko H; Robak T; Jaksic B; Rekhtman G; Kyrcz-Krzemień S; Vatutin M; Wu J; Sirard C; Hallek M; Engert A
    Lancet Oncol; 2011 Dec; 12(13):1204-13. PubMed ID: 21992852
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Medical comorbidities in patients with chronic lymphocytic leukaemia treated with idelalisib: analysis of two large randomised clinical trials.
    Gordon MJ; Huang J; Chan RJ; Bhargava P; Danilov AV
    Br J Haematol; 2021 Feb; 192(4):720-728. PubMed ID: 32599655
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study.
    Stilgenbauer S; Eichhorst B; Schetelig J; Coutre S; Seymour JF; Munir T; Puvvada SD; Wendtner CM; Roberts AW; Jurczak W; Mulligan SP; Böttcher S; Mobasher M; Zhu M; Desai M; Chyla B; Verdugo M; Enschede SH; Cerri E; Humerickhouse R; Gordon G; Hallek M; Wierda WG
    Lancet Oncol; 2016 Jun; 17(6):768-778. PubMed ID: 27178240
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Idelalisib: A Novel PI3Kδ Inhibitor for Chronic Lymphocytic Leukemia.
    Shah A; Mangaonkar A
    Ann Pharmacother; 2015 Oct; 49(10):1162-70. PubMed ID: 26185276
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rituximab maintenance versus observation following abbreviated induction with chemoimmunotherapy in elderly patients with previously untreated chronic lymphocytic leukaemia (CLL 2007 SA): an open-label, randomised phase 3 study.
    Dartigeas C; Van Den Neste E; Léger J; Maisonneuve H; Berthou C; Dilhuydy MS; De Guibert S; Leprêtre S; Béné MC; Nguyen-Khac F; Letestu R; Cymbalista F; Rodon P; Aurran-Schleinitz T; Vilque JP; Tournilhac O; Mahé B; Laribi K; Michallet AS; Delmer A; Feugier P; Lévy V; Delépine R; Colombat P; Leblond V; ;
    Lancet Haematol; 2018 Feb; 5(2):e82-e94. PubMed ID: 29275118
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rituximab maintenance versus observation alone in patients with chronic lymphocytic leukaemia who respond to first-line or second-line rituximab-containing chemoimmunotherapy: final results of the AGMT CLL-8a Mabtenance randomised trial.
    Greil R; Obrtlíková P; Smolej L; Kozák T; Steurer M; Andel J; Burgstaller S; Mikušková E; Gercheva L; Nösslinger T; Papajík T; Ladická M; Girschikofsky M; Hrubiško M; Jäger U; Fridrik M; Pecherstorfer M; Králiková E; Burcoveanu C; Spasov E; Petzer A; Mihaylov G; Raynov J; Oexle H; Zabernigg A; Flochová E; Palášthy S; Stehlíková O; Doubek M; Altenhofer P; Pleyer L; Melchardt T; Klingler A; Mayer J; Egle A
    Lancet Haematol; 2016 Jul; 3(7):e317-29. PubMed ID: 27374465
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia.
    Brown JR; Byrd JC; Coutre SE; Benson DM; Flinn IW; Wagner-Johnston ND; Spurgeon SE; Kahl BS; Bello C; Webb HK; Johnson DM; Peterman S; Li D; Jahn TM; Lannutti BJ; Ulrich RG; Yu AS; Miller LL; Furman RR
    Blood; 2014 May; 123(22):3390-7. PubMed ID: 24615777
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 50.